Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
MRUS Stock Chart & Stats
$95.95
-$0.87(-2.01%)
At close: 4:00 PM EST
$95.95
-$0.87(-2.01%)
Day’s Range― - ―
52-Week Range$33.19 - $96.20
Previous CloseN/A
Volume56.75K
Average Volume (3M)1.96M
Market Cap
$7.28B
Enterprise Value$6.50B
Total Cash (Recent Filing)$542.95M
Total Debt (Recent Filing)$10.52M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding75,844,580
10 Day Avg. Volume1,076,012
30 Day Avg. Volume1,961,105
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)4.17
Price to Sales (P/S)77.42
P/FCF Ratio-14.40
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue127.04
Enterprise Value/Gross Profit-58.41
Enterprise Value/Ebitda-20.09
Forecast
1Y Price Target
$97.71Price Target Upside1.83% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-5.73
Revenue Forecast (FY)$52.39M
Bulls Say, Bears Say
Bulls Say
Acquisition And Market PositionThe acquisition by Genmab is expected to close by early in the first quarter, potentially strengthening market position.
Clinical Trials And EfficacyMerus is ahead in clinical trials and will likely be approved first, maintaining an advantage over competitors in the HNSCC space.
Financial ProspectsThe Merus acquisition adds $3 billion+ potential with petosemtamab and a late-stage pipeline potential above $8 billion.
Bears Say
Data Interpretation ChallengesThe small sample size and the incorporation of both confirmed and unconfirmed responses in ORR makes data more difficult to interpret at this stage.
Immature DataThe dataset is small, and too immature to provide insight into durability.
Limited Efficacy In Later LinesIn the 3L+ setting, only 1 out of 14 patients responded to petosemtamab monotherapy, indicating limited efficacy in this difficult-to-treat population.
Merus News
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $33.19 and its highest was $96.20 in the past 12 months.
What is Merus NV’s market cap?
Merus NV’s market cap is $7.28B.
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Mar 04, 2026 which is in 108 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Oct 30, 2025. The company reported -$1.262 earnings per share for the quarter, beating the consensus estimate of -$1.293 by $0.031.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Merus NV have?
Merus NV has 75,844,580 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$1.262 in its last earnings report, beating expectations of -$1.293. Following the earnings report the stock price went up 0.264%.
Which hedge fund is a major shareholder of Merus NV?
Currently, no hedge funds are holding shares in MRUS
Merus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$97.71 (1.83% Upside)
$97.71 (1.83% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 742.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.21%
12-Months-Change
Fundamentals
Return on Equity
-51.57%
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
MRUS Stock 12 Month Forecast
Average Price Target
$97.71
▲(1.83% Upside)
Technical Analysis
PTC Therapeutics
―
Zai Lab
―
Krystal Biotech
―
Akero Therapeutics
―
Avidity Biosciences
―
Ownership Overview
0.15% Insiders
21.59% Mutual Funds
59.56% Other Institutional Investors
16.39% Public Companies and
Individual Investors